CordenPharma Colorado, a peptide drug substance Contract Development and Manufacturing Organization (CDMO), has leased 64,000 square feet at Flatiron Park’s 5505 Central—Boulder’s first purpose-built speculative lab building—near the existing CordenPharma Colorado facility.

Flatiron Park’s Boulder campus supports life science, quantum and technology tenants through resilient infrastructure, flexible building solutions, and a thoughtfully curated campus environment. CordenPharma Colorado’s 15-year lease reinforces Flatiron Park’s position as a critical hub for innovation, and validates BioMed Realty’s substantial, long-term investment in the Boulder innovation ecosystem.

CordenPharma Colorado will be the sole tenant at 5505 Central. The new LEED Gold-certified facility features robust power capacity, adaptable lab grids, advanced mechanical and utility systems, and efficient waste disposal to support complex scientific operations. Strategically located adjacent to CordenPharma Colorado’s large-scale peptide manufacturing facility, the space will house process development and analytical services, enabling seamless integration of advanced peptide Active Pharmaceutical Ingredient (API) production from development through commercialization.

Beyond Colorado, the expanded peptide development capabilities created at this location will be integrated into CordenPharma’s growing global network across Europe and the U.S.

“We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region,” said Michael Landau, Managing Director of CordenPharma Colorado. “With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder. As a CDMO, our Development Laboratories are foundational in delivering effective support to customers and their patients.”